Skip to content
value.today

PeproMene Bio, Inc.

🇺🇸 Irvine, California, USABiotechnologyFounded 2016
Total raised
$40 M
1 round on record
Latest round
$40 M
Jul 2017
First round on record
Jul 2017
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of PeproMene Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2017$40 MNo. 1$10 to $50 million

PeproMene Bio, Inc.: Raise no. 1, Jul 2017

Investors in this round

17 investors had bought by the notice of Jun 12, 2018: 16 accredited, 1 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
$1,000
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Hong Woo Kim · Executive Officer, Director
  • Yung Ki Park · Executive Officer, Director
  • Hyukjong Tae Lee · Director
  • Sun Tae Hwang · Director
  • Young Rae Choi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Hyo Kwan Lee, Associate Director, Operation. Source: SEC Form D, newest notice filed Jun 12, 2018. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • PeproMene Bio, Inc. had no revenue when it filed its newest notice of a funding round (Jun 2018).

    SEC Form D (revenue range) · Jun 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2018

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of PeproMene Bio, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 17 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by PeproMene Bio, Inc.
NameRoleNamed in
Hong Woo KimExecutive officerJun 2018
Yung Ki ParkExecutive officerJun 2018
Hong Woo KimDirectorJun 2018
Hyukjong Tae LeeDirectorJun 2018
Sun Tae HwangDirectorJun 2018
Young Rae ChoiDirectorJun 2018
Yung Ki ParkDirectorJun 2018